Please assess the completion status of the following clinical trial:

Trial Title: Heliox-Powered Albuterol Therapy in the Treatment of Children Admitted With Acute Asthma Exacerbation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 2 -18 years;~* Previous history of asthma;~* Hospital admission for acute asthma exacerbation;~* Clinical asthma score greater than or equal to 3~Exclusion Criteria:~* Less than 2 years old or over 18 years old;~* Known allergy or hypersensitivity to ß-agonists;~* Require mechanical ventilation (invasive or non-invasive);~* Require FiO2 \>0.4;~* Failure to obtain informed consent;~* Enrollment in another investigational drug or asthma protocol;~* Incipient respiratory failure including but limited to respiratory acidosis(pCO2\>60 torr), altered mental status and/or excessive work of breathing.

- Gender: ALL
- Minimum Age: 24 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Heliox-powered albuterol) (Type: EXPERIMENTAL): Group 1 (Heliox-Powered Albuterol) patients will receive all albuterol nebulizer treatments, including continuous therapy, powered by 70:30 Heliox.
- Group 2 (Oxygen-powered albuterol) (Type: ACTIVE_COMPARATOR): Group 2 (Oxygen-Powered Albuterol) patients will receive all albuterol nebulizer treatments, including continuous therapy, powered by 100% oxygen per usual standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).